A Phase 1 interventional study of KX01 0.01% (0.1 mg/g) and Placebo in Psoriasis, sponsored by PharmaEssentia. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-07-02.
Sponsored by PharmaEssentia · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase I dose escalation study to assess the safety, tolerability and activity of three different strengths of topical KX01 in the treatment of patients with plaque-type psoriasis.
This is a Phase I dose escalation study to assess the safety, tolerability and activity of three different strengths of topical KX01 (Tirbanibulin Ointment) in the treatment of patients with plaque-type psoriasis. The study will be performed in four stages as below.
Stage I: 6 patients (KX01 0.01% [0.1 mg/g]) + 2 patients (placebo); Stage II: 6 patients (KX01 0.1% [1.0 mg/g] + 2 patients (placebo); Stage III: 6 patients (KX01 1% [10 mg/g]) for 5 days; Stage IV: 6 patients (KX01 1% [10 mg/g]), duration escalation for up to 4 cycles.
If there's no major safety concern in the previous stage with an unanimous consent by the sponsor and the principle investigator, the study proceeded to the next stage.
The primary objective is to evaluate the safety and tolerability of three different strengths of KX01 ointment in patients with plaque-type psoriasis. The secondary objective is to gain evidence regarding the activity of three different strengths of KX01 ointment in patients with plaque-type psoriasis.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
This study's enrollment of 28 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Browse Psoriasis studies →PharmaEssentia is the lead sponsor of 17 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Six patients in the stage 1 will receive KX01 0.01% (0.1 mg/g) for 2 weeks, followed by 1-week wash-out, another 2-week treatment, and then 2-week follow-up.
Drug: KX01 0.01% (0.1 mg/g)
Two patients in the stage 1 will receive placebo treatment for 2 weeks, followed by 1-week wash-out, another 2-week treatment, and then 2-week follow-up.
Drug: Placebo
Six patients in the stage 2 will receive KX01 0.1% (1.0 mg/g) for 4 weeks, followed by 2-week follow-up.
Drug: KX01 0.1% (1.0 mg/g)
Two patients in the stage 2 will receive placebo treatment for 4 weeks, followed by 2-week follow-up.
Drug: Placebo
Six patients in stage 3 will receive 1% KX01 (10 mg/g) once daily for consecutive 5 days and then receive post-treatment follow-up on Day 6, 15 and 29.
Drug: KX01 1% (10 mg/g) for 5 days
Six patients in stage 4 will be treated with daily KX01 1% (10 mg/g) ointment for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles. And post-treatment follow-up visits will be conducted 14 days (Follow-up visit 1) and 28 days (Follow-up visit 2) after the end of cycle 4 treatment.
Drug: KX01 1% (10 mg/g) for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles
Drug page: Tirbanibulin
Stage 1: 6 patients (KX01 0.01% \[0.1 mg/g\])
Contains same excipients with KX01 but do not contain Tirbanibulin
Drug page: Tirbanibulin
Stage 2: 6 patients (KX01 0.1% \[1.0 mg/g\])
Drug page: Tirbanibulin
Stage 3: 6 patients (KX01 1% \[10 mg/g\]) for 5 days
Drug page: Tirbanibulin
Stage 4: 6 patients (KX01 1% \[10 mg/g\])for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles
Adverse event at Stage 1
Incidence of adverse event
Time frame: Day 50
Adverse event at Stage 2
Incidence of adverse event
Time frame: Day 43
Adverse event at Stage 3
Incidence of adverse event
Time frame: Day 29
Adverse event at Stage 4
Incidence of adverse event
Time frame: 28 days after the end of cycle 4 treatment (each cycle is 7 days)
Local tolerability score at Stage 1
4-point (0-3) rating scale; higher scores mean a worse outcome
Time frame: Day 50
Local tolerability score at Stage 2
4-point (0-3) rating scale; higher scores mean a worse outcome
Time frame: Day 43
Local tolerability score at Stage 3
4-point (0-3) rating scale; higher scores mean a worse outcome
Time frame: Day 29
Local tolerability score at Stage 4
4-point (0-3) rating scale; higher scores mean a worse outcome
Time frame: 28 days after the end of cycle 4 treatment (each cycle is 7 days)
Vital signs at Stage 1
any abnormal vital sign with clinical significance
Time frame: Day 50
Vital signs at Stage 2
any abnormal vital sign with clinical significance
Time frame: Day 43
Vital signs at Stage 3
any abnormal vital sign with clinical significance
Time frame: Day 29
Vital signs at Stage 4
any abnormal vital sign with clinical significance
Time frame: 28 days after the end of cycle 4 treatment (each cycle is 7 days)
12-lead ECG at Stage 1
any abnormal finding of 12-lead ECG with clinical significance
Time frame: Day 36
12-lead ECG at Stage 2
any abnormal finding of 12-lead ECG with clinical significance
Time frame: Day 29
12-lead ECG at Stage 3
any abnormal finding of 12-lead ECG with clinical significance
Time frame: Day 29
12-lead ECG at Stage 4
any abnormal finding of 12-lead ECG with clinical significance
Time frame: 28 days after the end of cycle 4 treatment (each cycle is 7 days)
Hematology assessments at Stage 1
any abnormal hematologic lab data with clinical significance
Time frame: Day 36
Clinical chemistry assessments at Stage 1
any abnormal chemical lab data with clinical significance
Time frame: Day 36
Urinalysis assessments at Stage 1
any abnormal urine lab data with clinically significant
Time frame: Day 36
Hematology assessments at Stage 2
any abnormal hematologic lab data with clinical significance
Time frame: Day 29
Clinical chemistry assessments at Stage 2
any abnormal chemical lab data with clinical significanc
Time frame: Day 29
Urinalysis assessments at Stage 2
any abnormal urine lab data with clinically significant
Time frame: Day 29
Hematology assessments at Stage 3
any abnormal hematologic lab data with clinical significance
Time frame: Day 29
Clinical chemistry assessments at Stage 3
any abnormal chemical lab data with clinical significanc
Time frame: Day 29
Urinalysis assessments at Stage 3
any abnormal urine lab data with clinically significant
Time frame: Day 29
Hematology assessments at Stage 4
any abnormal hematologic lab data with clinical significance
Time frame: 28 days after the end of cycle 4 treatment (each cycle is 7 days)
Clinical chemistry assessments at Stage 4
any abnormal chemical lab data with clinical significanc
Time frame: 28 days after the end of cycle 4 treatment (each cycle is 7 days)
Urinalysis assessments at Stage 4
any abnormal urine lab data with clinically significant
Time frame: 28 days after the end of cycle 4 treatment (each cycle is 7 days)
Change between baseline and end of treatment in target area score (TAS) at Stage 1
Change between baseline and end of treatment in TAS that evaluates the target lesion's erythema (0-4), plaque elevation (0-4) and scaling (0-4) on a five-point scale for each item (higher scores mean a worse outcome)
Time frame: Stage 1: Up to Day 36
Change between baseline and end of TAS at Stage 2
Change between baseline and end of treatment in TAS that evaluates the target lesion's erythema (0-4), plaque elevation (0-4) and scaling (0-4) on a five-point scale for each item
Time frame: Up to Day 29
Change between baseline and end of TAS at Stage 3
Change between baseline and end of treatment in TAS that evaluates the target lesion's erythema (0-4), plaque elevation (0-4) and scaling (0-4) on a five-point scale for each item
Time frame: Up to Day 6
Change between baseline and end of TAS at Stage 4
Change between baseline and end of treatment in TAS that evaluates the target lesion's erythema (0-4), plaque elevation (0-4) and scaling (0-4) on a five-point scale for each item
Time frame: Up to the end of cycle 4 treatment (each cycle is 7 days)
TAS 50 at Stage 1
≧50% reduction in TAS score from baseline at the end of treatment
Time frame: Up to Day 36
TAS 50 at Stage 2
≧50% reduction in TAS score from baseline at the end of treatment
Time frame: Up to Day 29
TAS 50 at Stage 3
≧50% reduction in TAS score from baseline at the end of treatment
Time frame: Up to Day 6
TAS 50 at Stage 4
≧50% reduction in TAS score from baseline at the end of treatment
Time frame: Up to the end of cycle 4 treatment (each cycle is 7 days)
Physician global assessment (PGA) score of the target lesion at the end of treatment of Stage 1
Achieving a score of "clear" (grade 0) or "almost clear" (grade 1) and at least 2 grade improvement from the baseline score in a 7-point score (0-6, higher scores mean a worse outcome).
Time frame: Up to Day 36
PGA score of the target lesion at the end of treatment of Stage 2
Achieving a score of "clear" (grade 0) or "almost clear" (grade 1) and at least 2 grade improvement from the baseline score in a 7-point score
Time frame: Up to Day 29
PGA score of the target lesion at the end of treatment of Stage 3
Achieving a score of "clear" (grade 0) or "almost clear" (grade 1) and at least 2 grade improvement from the baseline score in a 7-point score
Time frame: Up to Day 6
PGA score of the target lesion at the end of treatment of Stage 4
Achieving a score of "clear" (grade 0) or "almost clear" (grade 1) and at least 2 grade improvement from the baseline score in a 7-point score
Time frame: Up to the end of cycle 4 treatment (each cycle is 7 days)
Disease relapse at Stage 2
Relapse is the loss of more than 50% of TAS improvement from baseline in patients who achieve a clinically meaningful response. Clinical meaningful response is defined as a reduction of ≥50% in TAS from baseline during the treatment.
Time frame: Day 43
Disease relapse at Stage 3
Relapse is the loss of more than 50% of TAS improvement from baseline in patients who achieve a clinically meaningful response. Clinical meaningful response is defined as a reduction of ≥50% in TAS from baseline during the treatment.
Time frame: Day 15 and Day 29
Disease relapse at Stage 4
Relapse is the loss of more than 50% of TAS improvement from baseline in patients who achieve a clinically meaningful response. Clinical meaningful response is defined as a reduction of ≥50% in TAS from baseline during the treatment.
Time frame: 14 days after cycle 4 treatment and 28 days after cycle 4 treatment (each cycle is 7 days)
Plasma KX01 concentrations (ng/ml) at Stage 1
Detection of plasma KX01 concentrations (ng/ml)
Time frame: Up to Day 36
Plasma KX01 concentrations (ng/ml) at Stage 2
Detection of plasma KX01 concentrations (ng/ml)
Time frame: Up to Day 29
Plasma KX01 concentrations (ng/ml) at Stage 3
Detection of plasma KX01 concentrations (ng/ml)
Time frame: Up to Day 15
Plasma KX01 concentrations (ng/ml) at Stage 4
Detection of plasma KX01 concentrations (ng/ml)
Time frame: 14 days after cycle 4 treatment (each cycle is 7 days)
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2015 to primary completion in Mar 2021, 64 months.
Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 64 months is above that.
Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirbanibulin
PharmaEssentia